Michael Mayinger

[NonsparseOncologist @5_utr]

‼️ GROUQ-PCS 9

CRPC: ADT + enza vs ADT + Enza + SBRT to the conventionally (CT/MRI/bone scan) identified oligometastatic sites

Primary endpt: rPFS =
4.6 years in the SBRT group and 2.3 years in the ADT and Enza arm, HR 0.5 (0.28-0.88)

https://t.co/3caK0UG8vi

[Oncology Brothers @OncBrothers]

#GU25 highlights #CommunityOnc:

1. Radical ✂️ vs. XRT high risk PCa

2. #TALAPRO2: PARPi in M1 CRPC

3. #EnzaP: ARPi + LuPSMA in M1 CRPC

4. #NIAGARA update: Resectable MIBC

5. #EV302 update: Metastatic #BladderCancer

6. #CM9ER update: 1L mRCC

#OncTwitter #gism @ASCO

1/7

[Shankar Siva @_ShankarSiva]

❓Wondering whats new in stage IV #cancer? Incidence of mets in #breastcancer or #prostatecancer? Role of 🧬genomics, ☢️PET, #radonc or lifestyle mods?
🇺🇸🇨🇭🇨🇦🇧🇪🇮🇹🇫🇷🇦🇺 @EricLehrer and @NicholasZaorsky lead an international cast to address these questions https://t.co/8PDgcdMRI6

[Sean Collins Prostate SBRT @ USF Health @SbrtSean]

Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upr… https://t.co/VacxQyNwHe

[Shankar Siva @_ShankarSiva]

"Oligo"-no more! 🇨🇦ARREST phase I out now @IJROBP - @sueyom
➡️SABR to median=16 "poly"metastases in patients who had already exhausted multiple lines of systemic therapy
➡️4x dose levels (up to 6Gyx5).
➡️No safety signals, QoL maintained. https://t.co/ZIjhtg6RCJ Congrats! 👏👏

[Jonas Willmann, MD @jonas_willmann]

Prospective evidence to guide decision making on reirradiation is still scarce. So how are ongoing trials addressing the knowledge gaps?

Find it out in our systematic review of a clinical trials database 👇

https://t.co/gNWWzW61Hn

#radonc #OpenAccess

[Nicholas van As @nickva1]

Delighted to share the results of #PACE B trial, published in @NEJM today
5 fraction SBRT is non inferior to CRT!
https://t.co/9ja6OZFRab
@alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa

[Sean Collins Prostate SBRT @ USF Health @SbrtSean]

Is Prophylactic Pelvic Nodal Treatment Important in Radiation Therapy for Muscle Invasive Bladder Cancer?

Important Abstract Suggests that the Answer is NO!

[Shankar Siva @_ShankarSiva]

EMPIRE-2 trial #ASTRO24 - impact of Ga68 PSMA and 18F-fluciclovine PET on #prostatecancer post-prostatectomy #radiotherapy volumes. Conclusion is that both PET tracers moderately altered volumes @ASTRO_org #radonc

[Alex Louie MD, PhD @DrAlexLouie]

Adriatic is the new Pacific as durva improves PFS and OS in LS-SCLC! So proud of my mentor Prof. Suresh Senan who lead this effort - lots to unpack here on PCI, RT schedule, and choice of platinum chemo #LCSM #RadOnc @drdavidpalma @bslotman @_ShankarSiva @DrewMoghanaki

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial out in @EUplatinum

https://t.co/ln9jMk6uBr

The PACE-A trial is a phase 3⃣ randomized study comparing patient-reported outcomes between stereotactic body radiotherapy☢️ (SBRT) and prostatectomy in men with low- to intermediate-risk localized #ProstateCancer

It assessed health-related quality of life, focusing on urinary incontinence, bowel function, and sexual health two years after treatment.

Results showed that SBRT led to significantly less urinary incontinence and better sexual function, while prostatectomy resulted in better bowel scores.

However, SBRT was associated with slightly more bowel issues. These findings provide important insights for treatment decisions in localized prostate cancer.

@nickva1
@royalmarsdenNHS
@alison_tree
@DrTolan
@EmmaHall71

[Adam B. Weiner, MD @Adam_Weiner535]

🚨International Variations in Adherence to Quality Metrics for Locoregional #ProstateCancer🚨

⭐️We queried the 10-country cohort in the @Movember TrueNTH Global Registry (n=62k)

👉Significant international variations in 4 quality metrics (see Fig):
1⃣ Surveillance for low-risk
2⃣ Timely treatment for unfav-risk
3⃣ No staging imaging for fav-risk
4⃣ Staging imaging for unfav-risk

🔗 https://t.co/dKmiGtZd2R

🙏Co-authors
Anissa V. Nguyen, MS
Mark S. Litwin, MD, MPH
@AmarUKishan
@RobertReiterMD

[Annals of Oncology @Annals_Oncology]

initial data from SUC-SARC032 trial presented by @DKirschMDPhD radiotherapy & surgery +/- pembrolizumab in patients with resectable stage III #sarcoma (UPS or LPS)
🔷2yr DFS 53% vs 70%
🔷no statistically significant difference in LRFS & DDFS
🔷OS data immature
#ASCO24

[Drew Moghanaki @DrewMoghanaki]

10 years of experience at the University Hospital of Liège in Belgium (2010-2020) demonstrates the importance of >110% hotspots in lung SBRT plans. #radonc https://t.co/uJP2s1ikIE

[Michael Chuong @MikeChuongMD]

🔥🔥 Long-term outcomes from phase 2 SMART pancreas trial now in press 🔥🔥

➡️ 136 BRPC/LAPC pts, 50 Gy/5 fx on #MRidian
➡️ Median F/U 22.9 mo from dx, 14.2 mo from SMART
➡️ 2-yr OS 53.6% from dx, 40.5% from SMART
➡️ Grade 3+ late GI toxicity minimal

https://t.co/VKKIDntnFX

[Pierre Blanchard, MD @PBlanchardMD]

Hot off the press at @JCO_ASCO: prophylactic #radiotherapy for asymptomatic bone mets

RCT by @ErinGillespieMD et al:
✅decreased skeletal event with RT (1.6% vs 29%)
✅Improved OS
✅RCT
❌small sample, mostly single center, various tumors

Full paper: https://t.co/JKC3Q5IbKq

[Matthias Guckenberger @Mat_Guc]

PACE-B 5-years results presented at #ASTRO23 by @nickva1
👉 excellent outcome of >95% biochemical control in SBRT
👉 no difference in long-term toxicity

STANDARD OF CARE for favourable intermediate risk prostate cancer

[Shankar Siva @_ShankarSiva]

Two aussies 🇦🇺🦘 at the 🌏 stage #ASTRO23 👏🏽👏🏽
EMBARK study in #prostatecancer #pcsm demonstrates that patients with prior #radiotherapy benefit from enzalutamide +/- ADT in the high risk recurrent setting.

[Brian Lawenda MD @BLawenda]

The vast majority of T1NO, ER/PR+, HER- breast cancers have excellent outcomes w/ adjuvant RT alone. The addition of endocrine therapy after RT doesn’t improve LC or survival…but it does add years of side effects and cost. Patients need to know RT-alone is an option.

[Joost Verhoeff @joostverhoeff]

Great start of #SNOSTORM2023 in St. Louis @WUSTLmed @stopstormEU with @MartinsRaphae15 talking on clinical developments for cardiac ablative radiotherapy for VT #epeep

https://t.co/rodhArrXaI